CD40 transcriptomic expression patterns across malignancies: implications for clinical trials of CD40 agonists.

Cancer Immunol Immunother · 2025 · PMC12583269 · PMID 41182434

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0880

boldest claim

The sentences

showed a trendP = 0.052so close (0.05 < p ≤ 0.1)

This analysis confirmed that in the ICI-treated cohort, higher CD40 expression was significantly associated with longer OS (HR 0.991, 95% CI 0.985–0.997; P = 0.003) and showed a trend toward improved PFS (HR 0.995, 95% CI 0.990–1.000; P = 0.052).

also in 53,322 other papers

did not reach statistical significanceP = 0.088so close (0.05 < p ≤ 0.1)

In contrast, the association did not reach statistical significance in patients with low/moderate CD4/CD8 expression ( P = 0.088).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.